PRINCETON, NJ--Bristol-Myers Squibb Company has received FDA clearance
to market Etopophos (etoposide phosphate) for injection, a new
water-soluble version of its anticancer drug VePesid (etoposide).
Etopophos can be administered in as few as 5 minutes, representing
a marked advantage over the 30- to 60-minute infusion time required
for VePesid, the company said.
Etopophos can also be given to patients in higher concentrations
than VePesid, reducing by up to 1/50th the fluid volume infused.
The new version of the drug has the same indication as VePesid:
to be used in combination with other approved chemotherapy agents
as first-line treatment in patients with small-cell lung cancer
and in combination with other approved chemotherapy agents in
patients with refractory testicular tumors who have already received
appropriate surgery, chemotherapy, and radiotherapy.
"This new version of etoposide offers greater convenience
to both patients and the medical professionals who care for them,"
said Michelle Daniels, MD, director, Medical Information, Bristol-Myers
Squibb Oncology. "Patients may now spend a lot less time
in the clinic receiving their treatment."